Business
Cardiol Therapeutics Introducing Major Supply of Pharmaceutical CBD to Meet Supply Crunch -- CFN Media
Seattle, Washington--(Newsfile Corp. - January 30, 2019) - CFN Media Group ("CFN Media"), the ...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Cardiol Therapeutics Introducing Major Supply of Pharmaceutical CBD to Meet Supply Crunch -- CFN MediaSeattle, Washington--(Newsfile Corp. - January 30, 2019) - CFN Media Group (\"CFN Media\"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Cardiol Therapeutics' (TSX: CRDL) upcoming launch of its pharmaceutical CBD products, with the capacity to scale manufacturing to metric tonnes per year.Cannot view this video? Visit:https://www.youtube.com/watch?v=Ya0nHPZ5ObsIn Canada, registered medical patients have been able to access cannabis-derived cannabidiol (CBD) oils since 2001, and the government's move to legalize cannabis in October 2018 opened the adult-use market. According to an article by CBC, the result has been a shortage of medicinal CBD, though opinions vary on exact reasons for the current lack of supply. According to James O'Hara, of the advocacy group Canadians for Fair Access to Medical Marijuana, \"It's actually more than a supply issue. Really, it's something of a health crisis now. Unfortunately, there are no regulations in place to actually guarantee supply for the medical market.\"To view an enhanced version of this graphic, please visit:https://orders.newsfilecorp.com/files/5503/42549_4f2c7d65d4b54bb1_001full.jpgSource: New Frontier DataThe Canadian medical market is only expected to grow, with forecasts calling for more than $2 billion of spending by the end of 2020.On the pharmaceutical front, as science catches up after years of prohibition, research indicates CBD may have a wide array of health benefits. Companies across the globe are advancing drug candidates to address conditions ranging from seizures to inflammation to cancer. The opportunity is tremendous. For example, Epidiolex, the only FDA-approved CBD drug, to treat a small family of rare illnesses, is estimated to generate $625 million in international annual revenue by 2022.The questions underlying these trends are: Where will all the CBD come from? And more to the point, where will the pure pharmaceutical CBD, manufactured in Health Canada and FDA approved facilities that meet the strictest regulations, come from? Cardiol Therapeutics (TSX: CRDL) is providing these answers.Partnerships Drive CapabilityIn 2017, Cardiol secured an exclusive agreem...